A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?
Video navigation menu
- Broad picture of lipid reduction 00:14
- Concept of lifetime cumulative LDL-C exposure 01:24
- JUPITER: primary prevention trial with high-dose statin 02:10
- Why are additional agents beyond statins needed? 03:11
- PCSK9 inhibitors: evidence of effectiveness in several patients 04:15
- Development of PCSK9 inhibitors - from discovery to approval 06:13
- Residual risk 08:31
Educational objectives of this symposium were to:
- Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients at increased CV risk and with FH
- Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
- Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
- To explore treatment options in a statin-intolerant high risk patient in order to reach LDL-C goal
- Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
- Emphasize the need for outcomes data from clinical trials to apply implications and recommendations for practical lipid management
- Understand the implications of new ESC guidelines for lipid management
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).
Dr. Paul M Ridker, MD, MPH, is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention at the Brigham and Women’s Hospital in Boston.
Supported by unrestricted educational grants from Amgen, Pfizer, and Sanofi-Regeneron